Overview

A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain

Status:
Completed

Trial end date:
2006-05-01

Target enrollment:

Participant gender:

Summary

The primary objective was to demonstrate the superiority of OXN over placebo over time from the initial dose of study medication to multiple pain events (inadequate analgesia) during the double blind phase.

Phase:

Phase 3

Details

Lead Sponsor:

Mundipharma Research GmbH & Co KG

Treatments:

Naloxone
Oxycodone